Inflammation Clinical Trial
— Amp-NuOfficial title:
Nutritional Status, Eating Pattern and Inflammation Among Patients With Amputation of the Lower Limb - a Longitudinal Cohort Study
Verified date | January 2017 |
Source | Hvidovre University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Patients with non-traumatic lower limb amputation are characterized by; high age; majority
being men; multimorbidity; and high mortality. The patients comorbidities are related to
diabetes and cardiovascular disorders such as arteriosclerosis.
Major surgery induces a surgical stress response that initiates a catabolic metabolism.
Furthermore, the risk of systemic inflammatory response syndrome (SIRS) both before and
after amputation is high (3) as the most prominent indication for amputation is gangrene,
followed by non-healing or infected wounds. This leads to an impaired immune response and an
increased insulin resistance that also includes a cascade of impaired appetite regulation,
low dietary intake and reduced nutrient uptake form the intestine which increases
inflammation, loss of muscle and risk of severe complications.
Among healthy adults with a normal weight a slow speed of eating will result in a low
nutritional intake due to faster satiety experience.
Low appetite following major surgery is related to the regulation of hormone controlling the
appetite. Especially older patients experience variations in appetite that affect their
eating pattern such as eating speed and intake. It is therefore reasonable to assume that
the speed of eating and the total nutritional intake among older patients, who are exposed
to catabolic metabolism, are associated.
The hypothesis is that major surgery induces a change in patients' current eating pattern
that is measurable and can be identified as a surrogate measurement of the catabolic state
that is related to inflammation.
Eating Patterns are often described in clinical practice without engaging in nutritional
assessment of the patient. Whether the speed of eating is an objective marker of the current
nutritional status has not been established.
This study investigates patients undergoing lower limb amputation and their nutritional
status, eating pattern and inflammation and whether this is linked to the current degree of
disease. The purpose is to describe the development in nutritional status before and after
amputation and to investigate associations between patients eating pattern and nutritional
status to inflammatory and metabolic biomarkers reflecting the degree of disease.
Status | Active, not recruiting |
Enrollment | 49 |
Est. completion date | April 2017 |
Est. primary completion date | November 13, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years and older |
Eligibility |
Inclusion Criteria: - Having a medical indication for amputation - Admitted with a non healing wound on lower limb - Revision following previous amputation - Able to speak and understand Danish - able to give an informed consent Exclusion Criteria: - Traumatic or pathologic indication for amputation - Any or current use of narcotics - Major surgery within the last four weeks - If not amputated two weeks after admission |
Country | Name | City | State |
---|---|---|---|
Denmark | University Hospital of Copenhagen, Hvidovre | Hvidovre | Copenhagen |
Lead Sponsor | Collaborator |
---|---|
Hvidovre University Hospital |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | suPAR | Soluble urokinase plasminogen activator receptor: Biomarker of low-grade inflammation. suPAR are measured prior to surgery and on the 1, 3, 5 and 10 postoperative day and will be compared to patients daily intake of energy (kilojoule) and protein (gram) | From admission to ten days after surgery | |
Secondary | Inflammatory biomarkers such as IL6, IL10,IL18, TNF-a, MCP-1, sCD14, C reactive protein, expression of inflammatory genes from immucell | Biomarkers of low-grade inflammation. Inflammatory biomarkers will be measured in duplicates in serum or plasma using commercially available Luminex or ELISA kits according to the manufactures instructions. Cytokines with low systemic levels such as IL-6 and TNF-a will be measured with high sensitive kits to ensure detection. Samples are stored in a biobank established for the project at -80°C. Inflammatory biomarkers are measured simultaneously when all patients have been included. | From admission to ten days after surgery | |
Secondary | Metabolic biomarkers such as Insulin, Glucose, Adiponectin, Leptin, Ghrelin | Biomarkers of metabolic pathway Glucose is measured in blood at each visit using the HemoCue® system. All other metabolic biomarkers will be measured in duplicates in serum or plasma using commercially available Immulite, Luminex or ELISA kits according to the manufactures instructions. Samples are stored in a biobank established for the project at -80°C. Metabolic biomarkers except for glucose are measured simultaneously when all patients have been included. | From admission to ten days after surgery | |
Secondary | Postoperative LOS from surgery to medical stability (planned disharge) | The LOS are measured from the admission day to the unit and to the day the patients medical treatment are completed | From surgery to discharge | |
Secondary | Revisions or re-amputation | A Revision after amputation is defined as a surgical invasive procedure that aims to improve healing of the stump. A re-amputation is also defined as a surgical invasive procedure that includes amputation on a higher level | From surgery to discharge | |
Secondary | Severity of Infections | Infections are categorised in; sepsis, deep wound infections that is treated with antibiotics and superficially wound infections. | From surgery to discharge | |
Secondary | Eating patterns (eating time, intake ) | Eating pattern are measured as speed of eating (gram per minutes), the time for the total meal (minutes) and total intake (gram). | From surgery to ten days after surgery | |
Secondary | Secondary analysis 1: Descriptions of the nutritional status during hospitalisation 2: Nutritional status at disharge, dependency of morbitity | Nutritional intake is measured in protein (gram) and energy (Kilojoule). The nutritional intake is monitored daily from inclusion to 10 postoperative day. The nutritional status at discharge measured as difference in bodyweight from admission. Morbidity are defined as any chronical disease registered using ICG 10 code |
1: From admission to 10 postoperative day 2: Nutritional status at discharge | |
Secondary | Protein metabolism | Analysis of 24 hour urine sample among 10 patients undergoing major lower limb amputation. The protein metabolism will be measured as U-Carbamide (mmol) that are converted to the level of nitrogen and then compared to the daily protein intake to estimate the balance of protein. | Will be mesured on the 1, 5, and 10 postoperative day | |
Secondary | Monocytic Myeloid-derived Suppressor Cells (mMDSCs) | mMDSC are measured by FACS analyses in cryopreserved peripheral blood mononuclear cells | Measured at inclusion, and at day 10 after amputation, and at inclusion for Controls | |
Secondary | Sirtuin 1 (SIRT1) | SIRT1 along with other factors regulating hypoxia, inflammation, and catabolism such as hypoxia-inducible factor (HIF)-1a, nuclear factor k B (NF-kB), and forkhead box protein (Fox) O1 are measured in muscle biopsies from patients and controls. Muscle biopsies are submerged in All Protect (Quiagen) immediately after acquisition, and stored at least overnight, before transferral to a new cryo-vial. Muscle biopsies are stored at -80C until analyses. | Measured in muscle biopsies taken in the beginning of the amputation for patients, and at inclusion for Controls |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03995979 -
Inflammation and Protein Restriction
|
N/A | |
Completed |
NCT03255187 -
Effect of Dietary Supplemental Fish Oil in Alleviating Health Hazards Associated With Air Pollution
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT03577223 -
Egg Effects on the Immunomodulatory Properties of HDL
|
N/A | |
Completed |
NCT04383561 -
Relationship Between LRG and Periodontal Disease
|
N/A | |
Active, not recruiting |
NCT03622632 -
Pilot Study to Measure Uric Acid in Traumatized Patients: Determinants and Prognostic Association
|
||
Completed |
NCT06216015 -
Exercise Training and Kidney Transplantation
|
N/A | |
Completed |
NCT04856748 -
Nomogram to Diagnose Prostatic Inflammation (PIN) in Men With Lower Urinary Tract Symptoms
|
||
Completed |
NCT05529693 -
Efficacy of a Probiotic Strain on Level of Markers of Inflammation in an Elderly Population
|
N/A | |
Recruiting |
NCT05415397 -
Treating Immuno-metabolic Depression With Anti-inflammatory Drugs
|
Phase 3 | |
Recruiting |
NCT05670301 -
Flemish Joint Effort for Biomarker pRofiling in Inflammatory Systemic Diseases
|
N/A | |
Recruiting |
NCT04543877 -
WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study
|
Early Phase 1 | |
Recruiting |
NCT05775731 -
Markers of Inflammation and of the Pro-thrombotic State in Hospital Shift and Day Workers
|
||
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Completed |
NCT03429920 -
Effect of Fermented Soy Based Product on Cardiometabolic Risk Factors
|
N/A | |
Completed |
NCT06065241 -
Quantifiably Determine if the Botanical Formulation, LLP-01, Has a Significant Clinical Effect on Proteomic Inflammatory Biomarkers and Epigenetic Changes in Healthy, Older Individuals.
|
N/A | |
Completed |
NCT05864352 -
The Role of Dietary Titanium Dioxide on the Human Gut Microbiome and Health
|
||
Completed |
NCT03318731 -
Efficacy and Safety of Fenugreek Extract on Markers of Muscle Damage and Inflammation in Untrained Males
|
N/A | |
Not yet recruiting |
NCT06134076 -
Comparing Effects of Fermented and Unfermented Pulses and Gut Microbiota
|
N/A | |
Not yet recruiting |
NCT06159543 -
The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes
|
N/A |